{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"}],"units":"Participants"}],"title":"Post-baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams \\[mg\\]) on Day 1 of each 21-day cycle.","id":"OG000","title":"Atezolizumab"}],"paramType":"NUMBER","populationDescription":"The baseline ADA-evaluable population included patients who had a baseline ADA result. The post-baseline ADA-evaluable population included patients who had at least one post-baseline ADA result and had received at least one dose of that study treatment. Patients never dosed and patients without valid ADA records were not included in the analysis.","reportingStatus":"POSTED","timeFrame":"PRD (0 hr) on D1 of Cy1,2,3,4,8,12,16 (1 Cy=21 days) & every 8 cycles thereafter; at any time during visit on Cy1D8, study drug discontinuation, at least 90 days (maximum 150 days) after last dose of study drug (up to approximately 42 months)","title":"Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab","type":"PRIMARY","unitOfMeasure":"Percentage"}